| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Tsao F.-Y.; Liu T.-Y.; Hsieh C.-F.; Bair M.-J.; Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-Y.; Chen M.-J.; Chien-Chuan Chen; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C. |
| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; Kao J.-H.; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; CHIEH-CHANG CHEN; Fang Y.-J.; Hung H.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; CHIEH-CHANG CHEN; Lee Y.-C.; Chen M.-J.; Chien-Chuan Chen; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:37Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; CHIEH-CHANG CHEN; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chien-Chuan Chen; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; Chien-Chuan Chen; CHIEH-CHANG CHEN; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:35Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; CHIEH-CHANG CHEN; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chun-Chao Chang; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Wu M.-S.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:35Z |
Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; Chien-Chuan Chen; Chen Y.-N.; CHIEH-CHANG CHEN; Fang Y.-J.; Lin J.-T.; Wu M.-S.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:33Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chien-Chuan Chen; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:32Z |
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan
|
Chen M.-J.; Fang Y.-J.; Wu M.-S.; CHIEH-CHANG CHEN; Chen Y.-N.; Yu C.-C.; Kuo C.-C.; Chiu M.-C.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen H.-H.; Bair M.-J.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:32Z |
Comparison of DNA stabilizers and storage conditions on preserving fecal microbiota profiles
|
Liou J.-M.; Fang Y.-J.; Chuang E.Y.; Wu M.-S.; CHIEH-CHANG CHEN; Wu W.-K.; Chang C.-M.; Panyod S.; Lu T.-P. |
| 臺大學術典藏 |
2020-11-27T03:28:32Z |
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial
|
CHIEH-CHANG CHEN; Luo J.-C.; Fang Y.-J.; Lee J.-Y.; Kuo C.-C.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Bair M.-J.; Chen P.-Y.; Chou C.-K.; Chen C.-Y.; Chang C.-Y.; Hsu Y.-C.; Tseng C.-H.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen M.-J.; Shun C.-T.; Liu T.-Y.; Lee§ Y.-C.; Liou§ J.-M.; Wu§ M.-S.; and for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:31Z |
Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan
|
Fang Y.-J.; Chen M.-J.; CHIEH-CHANG CHEN; Lee J.-Y.; Yang T.-H.; Yu C.-C.; Chiu M.-C.; Kuo C.-C.; Weng Y.-J.; Bair M.-J.; Wu M.-S.; Luo J.-C.; Liou J.-M. |
| 臺大學術典藏 |
2020-11-17T02:45:18Z |
Comparison of DNA stabilizers and storage conditions on preserving fecal microbiota profiles
|
Wu M.-S.; Chuang E.Y.; Fang Y.-J.; TZU-PIN LU; Liou J.-M.; Panyod S.; Chang C.-M.; Wu W.-K.; Chen C.-C.; Chen C.-C.;Wu W.-K.;Chang C.-M.;Panyod S.;Tzu-Pin Lu;Liou J.-M.;Fang Y.-J.;Chuang E.Y.;Wu M.-S. |
| 臺大學術典藏 |
2020-11-03T08:19:39Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
CHEN-HUA LIU; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2020-11-03T07:37:19Z |
Suggested cutoff tumor size for management of small EUS-suspected gastric gastrointestinal stromal tumors
|
Wang H.-P.; WEI-CHIH LIAO; Chen J.-H.; Yang C.-S.; Sun M.-S.; Cheng T.-Y.; Fang Y.-J. |
| 臺大學術典藏 |
2020-11-02T02:04:52Z |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Sheng W.-H.; Wang H.-P.; MING-SHIANG WU; Lin J.-T. |
| 臺大學術典藏 |
2020-11-02T02:04:49Z |
Randomised clinical trial: High-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers
|
Chen C.-C.; Lee J.-Y.; Fang Y.-J.; Hsu S.-J.; Han M.-L.; Tseng P.-H.; Liou J.-M.; Hu F.-C.; Lin T.-L.; MING-SHIANG WU; Wang H.-P.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-02T02:04:47Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
MING-SHIANG WU; Lee Y.-C.; Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-02T02:04:45Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; MING-SHIANG WU; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L. |
| 臺大學術典藏 |
2020-11-02T02:04:33Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Lee Y.-C.; Wang W.-L.; Lee C.-T.; Tai C.-M.; MING-SHIANG WU; Bair M.-J.; Lin J.-T.; Sheu B.-S.; Wang H.-P.; Chang C.-C.; Yang T.-H.; Wu C.-Y.; Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Helicobacter Consortium; Taiwan Gastrointestinal Disease; Wang Y.-C. |
| 臺大學術典藏 |
2020-11-02T02:04:26Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Helicobacter Consortium; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; MING-SHIANG WU; the Taiwan Gastrointestinal Disease; Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C. |
| 臺大學術典藏 |
2020-11-02T02:04:26Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen�VNegative Patients
|
Lin J.-T.; Wu C.-Y.; Hung H.-W.; Fang Y.-J.; Chen C.-C.; Chiang M.-F.; Wang C.-S.; Yang T.-H.; Wang W.-L.; Kao J.-H.; MING-SHIANG WU; Chang C.-Y.; Hsu Y.-C.; Mo L.-R. |
| 臺大學術典藏 |
2020-11-02T02:04:25Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium; Chang C.-C.; Luo J.-C.; Yang T.-H.; Lee J.-Y.; Hsu Y.-C.; Chen C.-C.; Tseng C.-H.; Chen M.-J.; Lee Y.-C.; Chang C.-Y.; Bair M.-J.; Chen C.-C.; Fang Y.-J.; Liou J.-M. |
| 臺大學術典藏 |
2020-11-02T02:04:20Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; MING-SHIANG WU; Chen C.-C.; Chen C.-C.; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
